Cryoport FY2021 revenue $222.6M (+183% YoY); Q4 net loss $260.1M on $251.8M debt extinguishment

Cryoport, Inc.

2020-FY EPS reported -$6.19 revenue$222,608,000

FY2021 revenue $222.6M (+183% YoY); organic revenue from Cryoport Systems & CRYOGENE +40%.
Q4 revenue $56.4M (+17% YoY); Biopharma/Pharma revenue $46.3M (+18%).
Net loss Q4 $260.1M incl $251.8M non-cash debt extinguishment; Adj. EBITDA $0.8M.
Cash & short-term investments $628.8M at Dec 31, 2021; placed $402.5M 0.75% convertible notes.
Supports record 602 clinical trials (273 Phase 2, 74 Phase 3); fire at MVE facility expected Q1 impact $4-5M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.